Komen’s Research Investment
Susan G. Komen is the world’s largest breast cancer organization outside of the federal government, funding more breast cancer research than any other nonprofit while providing real-time help to those facing the disease. Since its founding in 1982, Komen has funded more than $956 million in research and provided more than $2.1 billion in funding to screening, education, treatment and psychosocial support programs.
Komen’s research program is funded in part by contributions from Komen’s nationwide Network of Affiliates, which directs 25 percent of funds raised locally to Komen’s national research program, while investing the remaining 75 percent into community outreach programs that serve local women and men facing breast cancer.
Since 1995, Komen South Carolina has funded $10,964,471 to community programs serving local women and men, while contributing $3,981,689 to Komen research since 1997.
More than $1.9 million invested in South Carolina
Currently funded Komen funded research in South Carolina includes:
Susan Steck, Ph.D., and Angela Murphy, Ph.D., of University of South Carolina ( $405,000) to create the Interdisciplinary Graduate Training Program in Cancer Disparities at the University of South Carolina. Doctoral level students will leverage the institution’s strength in health disparities to conduct research that aims to reduce and eliminate racial and ethnic disparities in breast cancer.
Adam Soloff, Ph.D., of Medical University of South Carolina ($450,000) for pre-clinical testing of a novel vaccine that induces highly specialized cells within the immune system to seek out cancer cells in combination with a new investigational drug, anti-PD-L1, which blocks the ability of cancer cells to hide from the immune system. If successful, this treatment strategy could not only kill existing breast cancer cells, but also produce long-term immune memory that will prevent breast cancer recurrence.
Martina McDermott, Ph.D., of University of South Carolina ($180,000) to determine whether the addition of a newly developed drug that targets a protein called CDK8 to ER and HER2-targeted therapies will increase the response to treatment and prevent the development of drug resistance.
Information about National and Global Research Programs
Thanks to the generosity of our donors and supporters, we’re funding lifesaving research in all areas of breast cancer, from basic biology to prevention to treatment and to survivorship. And with continued support, this scientific research will address some of the most pressing issues in breast cancer today:
- Identifying and improving methods of early detection
- Ensuring more accurate diagnoses
- Developing new approaches to prevention
- Enabling personalized treatments based on breast cancer subtypes and the genetic make-up of a tumor
Clinical trials are one of the final stages of a long and careful cancer research process. They can only take place after satisfactory information has been gathered from laboratory research, including cell cultures and animal models. Even the most promising scientific findings must first be proven to be safe and effective in clinical trials before they can be used as standard treatment. The cancer treatments that are used today were developed and tested in clinical trials. Through our research grants, we have supported more than 450 clinical trials.